MedTrace Logo

Rhupus Syndrome and Efficacy of Etanercept Treatment

NCT02766439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2016-05-09

No results posted yet for this study

Summary

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Conditions

  • Rhupus Syndrome, Etanercept

Interventions

DRUG

etanercept

25-mg etanercept injection subcutaneously twice a week

Sponsors & Collaborators

  • Yang Beibei

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-03-31
Completion
2015-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02766439 on ClinicalTrials.gov